Clinical and experimental oncology and immunology

Clinical and experimental oncology and immunology


Host Department
Department of Surgery, Oncology and Gastroenterology



Research Topic B

Abstract of the proposed UNIPhD research project


Retrovirus human T-lymphotropic virus type 1 (HTLV-1) causes an aggressive neoplasm of CD4+ T-cells termed adult T-cell leukemia/lymphoma(ATLL), that arises from the yet incompletely understood interplay that leads to T-cell immortalization. To date, there is no vaccine available to protect against HTLV-1 infection. Studies revealed alterations in the expression of many miRNAs in HTLV-1-infected cells that play roles in the viral life cycle, suggesting that miRNAs could be exploited as anti-HTLV-1 drugs. In addition, studies from the UniPD host lab indicated that selective killing of HTLV-1-infected cells can be obtained with ROS. We will examine the possible ability of miRNAs and ROS-inducing drugs to eliminate HTLV-1-infected cells. miRNAs and drugs will be delivered to cells by encapsulating them in particles conjugated with an antibody against CADM1-highly expressed on the surface of HTLV-1-infected cells-.



Short bio

I am a second-year Ph.D. student at UNIPD with a Master’s in Hematology and Blood Banking from Tehran, Iran, and a B.Sc. in Clinical Laboratory Science. Passionate about translating innovative ideas into practical solutions, my focus is on Hematology and Oncology. Committed to making meaningful contributions, I aim to advance medical knowledge and work towards finding cures for patients battling cancer.

Topic assigned to
Arezoo Darbandi


Project documents